论文部分内容阅读
目的 :探讨凋亡抑制基因 Bcl- 2和增殖细胞核抗原 ( PCNA)在乳腺导管浸润癌中的表达及与各临床参数的关系。方法 :免疫组织化学染色法对 35例乳腺导管浸润癌患者进行检测。结果 :Bcl- 2和 PCNA蛋白表达均为 68.6% ;Bcl- 2表达与癌组织分级及有无淋巴结转移呈负相关( P<0 .0 1 ) ,与雌激素 ( ER)水平及 5年生存期呈正相关 ( P<0 .0 1 ) ,与肿物大小无关 ;PCNA表达与癌组织分级及肿物大小呈正相关 ( P<0 .0 5 ) ,与 ER水平及 5年生存期呈负相关 ( P<0 .0 5 ) ,与淋巴结有无转移无关 ;Bcl- 2与 PCNA表达呈负相关。结论 :Bcl- 2高表达、ER水平高、PCNA表达低者生存期长、预后好 ,Bcl- 2和 PCNA可作为判定乳腺导管浸润癌恶性程度及预后的有效指标
Objective: To investigate the expression of apoptosis-suppressing genes Bcl-2 and PCNA in breast ductal invasive carcinoma and its relationship with clinical parameters. Methods: Immunohistochemical staining of 35 cases of invasive ductal carcinoma in breast cancer patients were detected. Results: The expressions of Bcl-2 and PCNA were both 68.6%. The expression of Bcl-2 was negatively correlated with the grade of tumor and lymph node metastasis (P <0.01), but not with the level of estrogen (ER) (P <0.01), and had no correlation with the size of the tumor. The expression of PCNA was positively correlated with the grade of tumor and the size of tumor (P <0.05), but negatively correlated with the level of ER and the 5-year survival (P <0.05), with or without lymph node metastasis; Bcl-2 and PCNA expression was negatively correlated. CONCLUSION: Bcl-2 overexpression, ER level is high, PCNA expression is low, the survival time is long, the prognosis is good. Bcl-2 and PCNA can be used as effective indicators to judge the degree and prognosis of invasive ductal carcinoma of breast